A new research project called BRIDGE was announced on Apr. 11, aiming to develop better strategies for diagnosing and treating aggressive forms of breast cancer. The initiative brings together the Instituto de Tecnologia Química e Biológica António Xavier of NOVA University of Lisbon (ITQB NOVA) and the Portuguese Institute of Oncology (IPOFG - Instituto Português de Oncologia de Lisboa Francisco Gentil).
The BRIDGE project will focus on finding new biomarkers—measurable biological signals in blood, tissues, or other samples—to help monitor how breast cancer evolves and tailor treatments to individual patients. Researchers will study small molecules on cell surfaces within the tumor microenvironment and investigate their connection to how tumors can suppress the immune system.
"With BRIDGE we aim to validate these findings using real patient samples and translate this knowledge into clinical applications." The IPOLFG will provide patient samples and support the clinical validation of the results. "By finding new biomarkers, we hope to contribute to more precise therapies," Catarina concludes.
Breast cancer remains a significant health concern worldwide. According to the World Health Organization, around 2.3 million women were diagnosed with breast cancer in 2022, resulting in about 670,000 deaths globally. Despite its prevalence, there are still no reliable predictors for progression in its most aggressive subtypes.
The BRIDGE project is funded under iNOVA4Health Lighthouse Projects (LHP) 2025, an initiative designed to support projects with strong translational potential by encouraging collaboration between basic research, technology development, and clinical practice. Over two years, BRIDGE will receive up to €75,000 in funding aimed at accelerating innovative solutions for major health challenges.
By expanding understanding of how tumors evade immune responses and identifying potential biomarkers for diagnosis and monitoring, researchers believe this work could lead not only to improved diagnostics but also help define new therapeutic targets.
